Numbers of ongoing advanced therapy clinical trials in the UK reached 187 in 2024, an increase of 7% compared to the previous year, according to the country’s Cell and Gene Therapy (CGT) Catapult.
The independent innovation and technology organization, which specializes in the advancement of CGTs, has published new insights into the advancement of the UK’s CGT industry in its 2024 advanced therapy medicinal product (ATMP) Clinical Trials Database.
In what the CGT Catapult calls an increasingly competitive global market, the UK remains a highly attractive destination for clinical studies, having representation in 9.5% of all global trials and almost 50% of those in Europe in 2024.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze